297 related articles for article (PubMed ID: 11907488)
1. Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19).
Christensen M; Tybring G; Mihara K; Yasui-Furokori N; Carrillo JA; Ramos SI; Andersson K; Dahl ML; Bertilsson L
Clin Pharmacol Ther; 2002 Mar; 71(3):141-52. PubMed ID: 11907488
[TBL] [Abstract][Full Text] [Related]
2. The major fluvoxamine metabolite in urine is formed by CYP2D6.
Spigset O; Axelsson S; Norström A; Hägg S; Dahlqvist R
Eur J Clin Pharmacol; 2001 Nov; 57(9):653-8. PubMed ID: 11791895
[TBL] [Abstract][Full Text] [Related]
3. Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes.
Yasui-Furukori N; Takahata T; Nakagami T; Yoshiya G; Inoue Y; Kaneko S; Tateishi T
Br J Clin Pharmacol; 2004 Apr; 57(4):487-94. PubMed ID: 15025747
[TBL] [Abstract][Full Text] [Related]
4. Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status.
Uno T; Shimizu M; Yasui-Furukori N; Sugawara K; Tateishi T
Br J Clin Pharmacol; 2006 Mar; 61(3):309-14. PubMed ID: 16487224
[TBL] [Abstract][Full Text] [Related]
5. Tolterodine does not affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine and omeprazole.
Brynne N; Böttiger Y; Hallén B; Bertilsson L
Br J Clin Pharmacol; 1999 Feb; 47(2):145-50. PubMed ID: 10190648
[TBL] [Abstract][Full Text] [Related]
6. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity.
Carrillo JA; Dahl ML; Svensson JO; Alm C; Rodríguez I; Bertilsson L
Clin Pharmacol Ther; 1996 Aug; 60(2):183-90. PubMed ID: 8823236
[TBL] [Abstract][Full Text] [Related]
7. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine.
Jeppesen U; Gram LF; Vistisen K; Loft S; Poulsen HE; Brøsen K
Eur J Clin Pharmacol; 1996; 51(1):73-8. PubMed ID: 8880055
[TBL] [Abstract][Full Text] [Related]
8. Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes.
Yasui-Furukori N; Saito M; Uno T; Takahata T; Sugawara K; Tateishi T
J Clin Pharmacol; 2004 Nov; 44(11):1223-9. PubMed ID: 15496639
[TBL] [Abstract][Full Text] [Related]
9. Non-linear fluvoxamine disposition.
Spigset O; Granberg K; Hägg S; Söderström E; Dahlqvist R
Br J Clin Pharmacol; 1998 Mar; 45(3):257-63. PubMed ID: 9517369
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole.
Andersson T; Holmberg J; Röhss K; Walan A
Br J Clin Pharmacol; 1998 Apr; 45(4):369-75. PubMed ID: 9578184
[TBL] [Abstract][Full Text] [Related]
11. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects.
Darwish M; Kirby M; Robertson P; Hellriegel ET
Clin Pharmacokinet; 2008; 47(1):61-74. PubMed ID: 18076219
[TBL] [Abstract][Full Text] [Related]
12. Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo.
Ozdemir V; Naranjo CA; Shulman RW; Herrmann N; Sellers EM; Reed K; Kalow W
J Clin Psychopharmacol; 1998 Jun; 18(3):198-207. PubMed ID: 9617978
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine.
Lobo ED; Bergstrom RF; Reddy S; Quinlan T; Chappell J; Hong Q; Ring B; Knadler MP
Clin Pharmacokinet; 2008; 47(3):191-202. PubMed ID: 18307373
[TBL] [Abstract][Full Text] [Related]
14. Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping.
Kashuba AD; Nafziger AN; Kearns GL; Leeder JS; Gotschall R; Rocci ML; Kulawy RW; Beck DJ; Bertino JS
Clin Pharmacol Ther; 1998 Sep; 64(3):257-68. PubMed ID: 9757149
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A.
Turpault S; Brian W; Van Horn R; Santoni A; Poitiers F; Donazzolo Y; Boulenc X
Br J Clin Pharmacol; 2009 Dec; 68(6):928-35. PubMed ID: 20002088
[TBL] [Abstract][Full Text] [Related]
16. Fluvoxamine impairs single-dose caffeine clearance without altering caffeine pharmacodynamics.
Culm-Merdek KE; von Moltke LL; Harmatz JS; Greenblatt DJ
Br J Clin Pharmacol; 2005 Nov; 60(5):486-93. PubMed ID: 16236038
[TBL] [Abstract][Full Text] [Related]
17. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
Streetman DS; Bleakley JF; Kim JS; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577
[TBL] [Abstract][Full Text] [Related]
18. The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics.
Ishizawa Y; Yasui-Furukori N; Takahata T; Sasaki M; Tateishi T
Clin Pharmacokinet; 2005; 44(11):1179-89. PubMed ID: 16231968
[TBL] [Abstract][Full Text] [Related]
19. Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine.
Miura M; Tada H; Yasui-Furukori N; Uno T; Sugawara K; Tateishi T; Suzuki T
Br J Clin Pharmacol; 2005 Jul; 60(1):61-8. PubMed ID: 15963095
[TBL] [Abstract][Full Text] [Related]
20. In Vivo Assessment of the Effect of CYP1A2 Inhibition and Induction on Pomalidomide Pharmacokinetics in Healthy Subjects.
Li Y; Liu L; Wang X; Zhang C; Reyes J; Hoffmann M; Palmisano M; Zhou S
J Clin Pharmacol; 2018 Oct; 58(10):1295-1304. PubMed ID: 29762875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]